Form 4: Director Jennifer Cook Receives Denali Equity Grant

Denali Therapeutics director Jennifer E. Cook was granted 6,408 restricted stock units and 19,226 stock options.

Summary

• Director Jennifer E. Cook acquired 6,408 Restricted Stock Units (RSUs) on June 3, 2026.
• Director Jennifer E. Cook was granted 19,226 stock options with an exercise price of $19.66 on June 3, 2026.
• Both the RSUs and stock options are scheduled to vest on the earlier of the one-year anniversary of the grant date or the day preceding the next annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation with no material impact on company operations or financial health.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• None identified; this is a standard compensatory equity grant for a board member.

Risks

• Standard market risks associated with equity-based compensation and stock price volatility.

Future Outlook

The equity grants vest in one year, signaling continued board commitment to the company's long-term strategic objectives.

Industry Context

StockSavvy.ai notes that equity grants to board members are standard practice in the biotechnology sector to ensure alignment between leadership and shareholders, particularly for companies in the R&D phase.

Comparison to Industry Standards

• The grant structure and vesting schedule are consistent with standard corporate governance practices for NASDAQ-listed biotechnology firms.

Stakeholder Impact

• Minimal impact on shareholders; represents standard director compensation.

Next Steps

• Vesting of RSUs and options on the earlier of June 3, 2027, or the day before the next annual meeting.

Key Dates

Keywords

Denali Therapeutics, DNLI, Form 4, Insider Transaction, Equity Compensation, Director Stock Grant